Medidata Solutions and Cytel Inc. First to Integrate Flexible Patient Randomization in EDC Platform for Clinical Trials
Combined Advanced Technologies Enable Both Traditional and Adaptive Clinical Trials
Debuting at DIA Annual Meeting in Medidata Booth # 229
New York, NY, and Cambridge, MA, June 19, 2006-Medidata Solutions Worldwide and Cytel Inc. today announced a major advancement toward dramatically increasing efficiencies in the biopharmaceutical clinical development process. The companies have combined their respective expertise in electronic data capture (EDC) and flexible patient randomization to offer clinical study sponsors the ability to, for the first time, randomize patients in all types of trials-both traditional and adaptive-directly through an EDC system.
Medidata and Cytel have successfully integrated Cytel's FlexRandomizer® engine into Rave, Medidata's popular Web-based EDC system. Most clinical trials today use multiple data entry tools, including one tool for capture of the majority of clinical trial data and another for patient randomization. Now, both of these tasks can be completed through a single interface provided by Medidata Rave®. Randomization and eligibility criteria are checked uniformly across all investigator sites, accrual of study patients is monitored in real-time, treatments can be adjusted to patients' dose responses or other adaptive algorithms can be applied, and all randomization data is securely maintained within one system.
These features result in increased efficiencies in study conduct, reduced costs, and most importantly, increased patient safety. Unifying EDC with flexible randomization offers even greater advantages in facilitating and implementing adaptive clinical trial methodologies.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
